JP2016512214A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512214A5
JP2016512214A5 JP2015562176A JP2015562176A JP2016512214A5 JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5 JP 2015562176 A JP2015562176 A JP 2015562176A JP 2015562176 A JP2015562176 A JP 2015562176A JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5
Authority
JP
Japan
Prior art keywords
bispecific antibody
epitope
amino acid
tfpi
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562176A
Other languages
English (en)
Japanese (ja)
Other versions
JP6586016B2 (ja
JP2016512214A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055055 external-priority patent/WO2014140240A1/en
Publication of JP2016512214A publication Critical patent/JP2016512214A/ja
Publication of JP2016512214A5 publication Critical patent/JP2016512214A5/ja
Application granted granted Critical
Publication of JP6586016B2 publication Critical patent/JP6586016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562176A 2013-03-15 2014-03-14 組織因子系凝固インヒビター上の2つのエピトープに特異的に結合することが可能な抗体 Active JP6586016B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361789274P 2013-03-15 2013-03-15
EP13159515.9 2013-03-15
EP13159515 2013-03-15
US61/789,274 2013-03-15
PCT/EP2014/055055 WO2014140240A1 (en) 2013-03-15 2014-03-14 Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

Publications (3)

Publication Number Publication Date
JP2016512214A JP2016512214A (ja) 2016-04-25
JP2016512214A5 true JP2016512214A5 (enExample) 2017-04-20
JP6586016B2 JP6586016B2 (ja) 2019-10-02

Family

ID=47877935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562176A Active JP6586016B2 (ja) 2013-03-15 2014-03-14 組織因子系凝固インヒビター上の2つのエピトープに特異的に結合することが可能な抗体

Country Status (6)

Country Link
US (2) US9896513B2 (enExample)
EP (1) EP2970499B1 (enExample)
JP (1) JP6586016B2 (enExample)
CN (1) CN105209497B (enExample)
ES (1) ES2926773T3 (enExample)
WO (1) WO2014140240A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101745394B1 (ko) 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
CN110066339A (zh) * 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
US10457743B2 (en) * 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
PE20160953A1 (es) * 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
SG10201909173PA (en) 2015-04-01 2019-11-28 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
PE20240142A1 (es) * 2015-08-19 2024-02-01 Pfizer Anticuerpos inhibidores via del factor tisular y usos de los mismos
CN106554420A (zh) * 2015-09-30 2017-04-05 上海众合医药科技股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
EP3388838B1 (en) * 2016-01-29 2022-02-16 Sony Group Corporation Blood coagulation analysis
EP3689419A1 (en) 2016-11-01 2020-08-05 AnaptysBio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CN110382000A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗tim-3抗体治疗癌症的方法
CN113645995A (zh) 2018-10-11 2021-11-12 辉瑞公司 Tfpi拮抗剂的剂量方案
JP2022506696A (ja) * 2018-11-07 2022-01-17 ボーダックス バイオ インコーポレーテッド Ivメロキシカムにより血小板機能異常症の対象を治療する方法
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN110156890B (zh) * 2019-04-09 2021-02-02 苏州大学 Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
AU5526690A (en) 1989-04-19 1990-11-29 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0539975A1 (en) * 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ ノルディスク アクティーゼルスカブ ラミニン−5γ2結合性ペプチド、その関連組成物およびその使用
BRPI0611570A2 (pt) 2005-06-15 2011-02-22 Novo Nordisk Healthcare Ag métodos para fixar covalentemente peg a um polipeptìdeo e para modificar propriedades farmacológicas de hormÈnio de crescimento, composto e sais, pró-drogas ou solvatos farmaceuticamente aceitáveis do mesmo, hormÈnio de crescimento humano, composição farmacêutica, método para tratamento de doença e, uso de um composto
KR101745394B1 (ko) * 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
CN102300876A (zh) 2008-12-22 2011-12-28 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂(tfpi)的抗体
CN103080135B (zh) 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
CA2831907C (en) * 2011-04-01 2020-03-24 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Similar Documents

Publication Publication Date Title
JP2016512214A5 (enExample)
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
AR075798A1 (es) Proteinas de union a il-17 (interleuquina 17)
HRP20220811T1 (hr) Agonistička sredstva za vezanje tnf receptora
JP2017529097A5 (enExample)
HRP20150439T1 (hr) Protutijela za humani angiopoietin 2
JP2017532313A5 (enExample)
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
HRP20200034T1 (hr) Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka
PE20181363A1 (es) Variantes optimizadas de anticuerpos anti-vegf
JP2017113019A5 (enExample)
HRP20161656T4 (hr) Sredstva za vezanje na cd33
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
IL299282B1 (en) Enhanced variable complexes of immunoglobulins
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
EA201391761A1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
JP2017508475A5 (enExample)
RU2013140350A (ru) Антитела против человеческого il33r и их применение
WO2017060322A3 (en) Ptefb-inhibitor-adc